Review paper<br>Current position of nebivolol in the treatment of cardiovascular diseases

Agata Dąbrowa-Bielecka; Jacek Rysz; Maciej Banach

eISSN: 2084-9877
ISSN: 1896-9666

Przegląd Kardiodiabetologiczny/Cardio-Diabetological Review

Current issue Archive About the journal Contact Instructions for authors

3/2009
vol. 4

Send email

Copy url:

abstract:

Review paper
Current position of nebivolol in the treatment of cardiovascular diseases

Agata Dąbrowa-Bielecka

,

Jacek Rysz

,

Maciej Banach

Przegląd Kardiodiabetologiczny 2009; 4 (3): 106–113

Online publish date: 2009/10/22

View full text Get citation

Nebivolol is a highly selective β-adrenolytic drug of the 3rd generation with the additional vasodilatative function depending on the releasing of endogenous nitric oxide (NO). Many available studies discovered the second level of therapeutic properties of nebivolol – very beneficial influence on metabolic and humoral causes of heart failure and showed very large potential of this drug in the prevention and treatment of the phenomenon leading to heart dysfunction.

keywords:

Review paperCurrent position of nebivolol in the treatment of cardiovascular diseases

Agata Dąbrowa-Bielecka , Jacek Rysz , Maciej Banach

endothelium, heart failure, hypertension, nebivolol

Review paper
Current position of nebivolol in the treatment of cardiovascular diseases

Agata Dąbrowa-Bielecka

,

Jacek Rysz

,

Maciej Banach